Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a highly lethal hepatobiliary cancer, and very few patients can undergo surgery. The prognosis of advanced ICC is poor, especially in patients who progress after first-line chemotherapy, with a median overall survival of less than 10 months. CASE...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jun-Wei, Yang, Xiaobo, Pan, Boju, Xu, Yiyao, Lu, Xin, Zhao, Hai-tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041738/
https://www.ncbi.nlm.nih.gov/pubmed/36973682
http://dx.doi.org/10.1186/s12957-023-02983-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041738/
https://www.ncbi.nlm.nih.gov/pubmed/36973682
http://dx.doi.org/10.1186/s12957-023-02983-1

Ejemplares similares